Metagenomi Appoints Pamela Wapnick, MBA, as Chief Financial Officer

Metageno­mi, a pre­ci­sion genet­ic med­i­cines com­pa­ny com­mit­ted to devel­op­ing cura­tive ther­a­peu­tics for patients by lever­ag­ing its metage­nomics-derived genome edit­ing tool­box, named Pamela Wap­nick, MBA, as Chief Finan­cial Officer.

Pamela Wap­nick has more than 20 years of diver­si­fied finan­cial lead­er­ship expe­ri­ence span­ning strate­gic and oper­a­tional finance roles. Pri­or to join­ing Metageno­mi, Pamela served as Chief Finan­cial Offi­cer at sev­er­al biotech and med­ical tech­nol­o­gy com­pa­nies includ­ing Dial­i­ty, Cap­si­da Bio­ther­a­peu­tics, and Gray­bug Vision, where she built the finance func­tions and led finan­cial plan­ning and strat­e­gy. As Chief Finan­cial Offi­cer at True North Ther­a­peu­tics, Pamela com­plet­ed prepa­ra­tions for an ini­tial pub­lic offer­ing before the company’s acqui­si­tion by Biover­a­tiv. Pri­or to that, she served in var­i­ous exec­u­tive lead­er­ship roles at Amgen, includ­ing Cor­po­rate Trea­sur­er and Vice Pres­i­dent R&D Finance, where she was respon­si­ble for a $3 bil­lion glob­al R&D bud­get focused on advanc­ing research and pipeline pro­grams.

Pamela holds an MBA from Colum­bia Uni­ver­si­ty and a BA in Eco­nom­ics from Welles­ley College.